ARS Pharmaceuticals, Inc. (SPRY) stock
Close on Nov 11, 2026Market cap $392.82MP/E –Yield –
ARS Pharmaceuticals, Inc. saw revenue fall 14.5% to $122.14M over the twelve months to Sep 30, 2026. Free cash flow was -$183.07M. At the latest close the market valued the company at $392.82M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $392.82M
- P/E ratio
- –
- Price to sales
- 3.22
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -46.60%
Fundamentals
- Revenue
- $122.14M
- Net income
- -$199.87M
- EPS, diluted
- -$2.02
- Free cash flow
- -$183.07M
- Book value per share
- -$0.12
- Diluted shares
- 100M
Trading
- Next earnings
- Mar 8, 2027 (estimated, before the open)
- Previous close
- $3.57
- Open
- $3.57
- Day's range
- $3.57 – $4.13
- Volume
- 3,845,862
- Average volume (20 days)
- 2,338,327
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 1.41
- 52-week range
- $2.44 – $13.15
- RSI (14 days)
- 54.4
- Volatility (1 year)
- 78.0%
- Relative volume
- 2.01×
- WACC
- 11.9%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SPRY | S&P 500 | Difference | SPRY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.6% | -2.4% | −4.2 pts | ||
| 3 months | -33.6% | -1.2% | −32.5 pts | ||
| Year to date | -66.1% | +12.3% | −78.4 pts | ||
| 1 year | -55.0% | +12.4% | −67.4 pts | ||
| 3 years | +5.9% | +78.8% | −72.9 pts | +1.9% | +21.4% |
| 5 years | -53.1% | +75.2% | −128.3 pts | -14.0% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ARS Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About ARS Pharmaceuticals
Pharmaceutical Preparations
ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the commercialization and development of emergency treatments for severe Type I allergic reactions, including anaphylaxis. The company's principal product is neffy (marketed as EURneffy in the European Union and the United Kingdom), a needle-free intranasal epinephrine spray. Formulated with an absorption enhancer to deliver low-dose epinephrine safely without injections, neffy is offered in 2 mg and 1 mg doses. ARS Pharmaceuticals serves adult and pediatric allergy patients, partnering with and marketing to allergists, pediatricians, primary care doctors, and school health programs.
Company profile, executives and historyARS Pharmaceuticals stock: common questions
What is ARS Pharmaceuticals's stock price?
SPRY closed at $3.95 on Nov 11, 2026, up 10.64% on the day. Over the past 52 weeks it traded between $2.44 and $13.15.
What is ARS Pharmaceuticals's market cap?
ARS Pharmaceuticals was worth $392.82M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SPRY's P/E ratio?
ARS Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.02), so it has no meaningful P/E ratio.
How much revenue does ARS Pharmaceuticals make?
ARS Pharmaceuticals reported revenue of $122.14M for the twelve months to Sep 30, 2026, down 14.5% from a year earlier.
Does ARS Pharmaceuticals pay a dividend?
No. ARS Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does ARS Pharmaceuticals report earnings next?
ARS Pharmaceuticals is expected to report Q4 FY2026 results on Mar 8, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has SPRY stock performed over the past year?
Including dividends, SPRY returned -55.0% over the past year, against +12.4% for the S&P 500.
How many SPRY shares are sold short?
19M shares were sold short at the latest FINRA report, 35.85% of the float, or 11.1 days of average trading volume.
Who are ARS Pharmaceuticals's competitors?
Companies most similar to ARS Pharmaceuticals by business, industry and size include ZVRA, ETON, AGIO, AQST, KPTI.
See a number that looks wrong?